NASDAQ: AIXCAixcrypto Holdings Inc Stock
$2.88-0.33 (-10.28%)
Updated Nov 19, 2025
AIXC Price
$2.88
Fair Value Price
$3.25
Market Cap
$14.86M
52 Week Low
$1.61
52 Week High
$8.81
P/E
-24x
P/B
0.39x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.09M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$7M
Beta
0.68
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AIXC Overview
A clinical-stage therapeutics company developing treatments for cancer and infectious diseases, including DNA-based therapeutics, small-molecule oncology drugs, and immune-modulating agents. The company previously manufactured FDA-cleared diagnostic devices before refocusing on biotechnology.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AIXC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AIXC
Ranked#339 of 481
Ranked#339 of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.48 | A | |
| $101.32 | A | |
| $15.20 | A |
Be the first to know about important AIXC news, forecast changes, insider trades & much more!
AIXC News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AIXC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AIXC ($2.88) is undervalued by 11.34% relative to our estimate of its Fair Value price of $3.25 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AIXC ($2.88) is not significantly undervalued (11.34%) relative to our estimate of its Fair Value price of $3.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AIXC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AIXC due diligence checks available for Premium users.
Valuation
AIXC fair value
Fair Value of AIXC stock based on Discounted Cash Flow (DCF)
Price
$2.88
Fair Value
$3.25
Undervalued by
11.34%
AIXC ($2.88) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AIXC ($2.88) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AIXC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AIXC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-24x
Industry
270.66x
Market
43.97x
AIXC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.39x
Industry
5.12x
AIXC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AIXC's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.9M
Profit Margin
0%
AIXC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$43.5M
Liabilities
$4.9M
Debt to equity
0.13
AIXC's short-term assets ($43.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AIXC's short-term assets ($43.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AIXC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AIXC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.1M
Investing
-$291.0k
Financing
$40.9M
AIXC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AIXC vs Biotech Stocks
Aixcrypto Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.